SCHEMBL8305437

SCHEMBL8305437

Cc1ccc(N2CCNC2=O)c(Cl)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
POLB P06746 1/20 0.41
METAP2 P50579 1/20 0.40
CMA1 P23946 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 1/20 0.38
HPGD P15428 1/20 0.38
HTT P42858 1/20 0.38
P2RX7 Q99572 1/20 0.38
HSD17B10 Q99714 1/20 0.38
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
HTR1A P08908 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
HTR3A P46098 1/20 0.37
ALOX5 P09917 1/20 0.37
CRHR1 P34998 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8306647 0.91 SMN1; SMN2 (0.47) MEN1KMT2APOLBMETAP2SMN1; SMN2
SCHEMBL30124549 0.84 GLA (0.39) MEN1KMT2APOLBCMA1ALDH1A1
SCHEMBL16531970 0.84 GLA (0.39) MEN1KMT2APOLBCMA1ALDH1A1
SCHEMBL8305765 0.83 NPSR1 (0.46) MEN1KMT2APOLBSMN1; SMN2ALDH1A1
SCHEMBL16701822 0.82 ALDH1A1 (0.53) POLBCMA1SMN1; SMN2ALDH1A1KDM4E
SCHEMBL8305608 0.81 SCN9A (0.42) MEN1KMT2APOLBCMA1ALDH1A1
SCHEMBL11293301 0.81 CMA1 (0.36) POLBCMA1ALDH1A1P2RX7CYP2C9
SCHEMBL8306364 0.80 SLC6A2 (0.46) METAP2ALDH1A1P2RX7HSD17B10CYP1A2
SCHEMBL19957302 0.80 CRHR1 (0.43) KMT2AP2RX7HSD17B10HTR1AHTR3A
SCHEMBL25667297 0.78 CRBN (0.55) MEN1KMT2AMETAP2ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070135428-A1 LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS QIAO JENNIFER X 2007-06-14 US disclosed
US-20070135428-A1 LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS QIAO JENNIFER X 2007-06-14 US disclosed
US-7205318-B2 Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-04-17 US disclosed
WO-2004082687-A1 LACTAM-CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135428-A1 LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS F12, F2, PEPD MEN1 228/4885KMT2A 1997/4885POLB 2080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.